B-cell receptor specific for Human Papillomavirus type 16 L1 protein (HPV16 L1 BCR)

The B-cell receptor (BCR) specific for Human Papillomavirus type 16 (HPV16) L1 conformational epitopes is a critical component of the adaptive immune system's defense against HPV infection (PMID: 15170407). These receptors are membrane-bound immunoglobulins expressed on the surface of B cells that specifically recognize the three-dimensional structure of the HPV16 major capsid protein, L1, typically presented in the form of virus-like particles (VLPs) (PMID: 23015013). Upon binding to these conformational epitopes, the BCR triggers intracellular signaling pathways that lead to B-cell activation, clonal expansion, and the eventual secretion of high-affinity neutralizing antibodies (PMID: 11544335). These antibodies are essential for preventing the virus from entering host epithelial cells, thereby protecting against persistent infection and the subsequent development of cervical, anogenital, and oropharyngeal cancers (NCI, 2023). Therapeutic interventions, primarily prophylactic vaccines like Gardasil and Cervarix, utilize recombinant VLPs to target these specific BCRs and induce long-term immunological memory (WHO, 2022). The high specificity of these receptors for conformational rather than linear epitopes ensures that the immune response is directed toward the infectious virion structure (PMID: 9047251).

Other names

HPV16 L1-specific B-cell receptorAnti-HPV16 L1 BCRHuman Papillomavirus type 16 L1-specific immunoglobulinHPV16 L1-specific BCR

Virus-like particles (VLPs) in vaccines act as potent immunogens that bind to and cross-link HPV16 L1-specific BCRs, stimulating the production of neutralizing antibodies and the formation of memory B cells (PMID: 15170407).